Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Imatinib-Resistant/Intolerant Accelerated Phase CML
NCT00101647Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2004
- Primary completion
- Aug 2006
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 23
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Bristol Myers Squibb. Started Dec 2004; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00101647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101647.